Document Detail

Solid-state interaction of stearic acid with povidone and its effect on dissolution stability of capsules.
MedLine Citation:
PMID:  18194844     Owner:  NLM     Status:  MEDLINE    
Capsule formulations of two drugs under development showed slower dissolution upon storage; Drug A, after 2.5 weeks at 40 degrees C/23% RH and 4 weeks at 30 degrees C/60% RH, and Drug B, after 6 weeks at 50 degrees C and 40 degrees C/75% RH. The formulations of both drugs contained povidone as a binder and stearic acid as a lubricant. Replacement of stearic acid by magnesium stearate from the formulation of Drug B, which was selected for further studies, provided rapid dissolution profiles under similar storage conditions with no change occurring on storage. In order to investigate the role of stearic acid further, binary mixtures of stearic acid with the drugs and other excipients used in their respective formulations were prepared and stored at 40 degrees C/75% RH and 50 degrees C. After 1 week of storage, it was observed that povidone and stearic acid mixture formed a transparent, hard, glass-like insoluble substance. It is hypothesized that the substance formed by the interaction can reduce the porosity of the granules and thereby reduces the ingress of the dissolution medium leading to slower dissolution. The infrared (IR) spectra of the glass-like substance showed a slight broadening of the povidone carbonyl band at 1662 cm(-1). The powder X-ray diffraction of the stored mixture showed that the crystallinity of stearic acid was lost. Furthermore, repeated heating and cooling cycles of povidone and stearic acid mixtures in various proportions using differential scanning calorimetry (DSC) showed that recrystallization of stearic acid from its melt was strongly affected by the presence of increasing amounts of povidone. Based on the observed solid-state interaction, a combination of stearic and povidone should be avoided for immediate release formulations.
D Desai; S Kothari; M Huang
Related Documents :
8477964 - Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy.
10205204 - Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octre...
12774024 - Hydrophilic but not hydrophobic bile acids prevent gallbladder muscle dysfunction in ac...
16432164 - Enhancement of dna topoisomerase i inhibitor-induced apoptosis by ursodeoxycholic acid.
17973074 - Alpha-amino acid behaves differently from beta- or gamma-amino acids as treated by trim...
17275064 - Homogeneous iron-catalyzed photochemical degradation of muconic acid in water.
Publication Detail:
Type:  Journal Article     Date:  2007-11-29
Journal Detail:
Title:  International journal of pharmaceutics     Volume:  354     ISSN:  0378-5173     ISO Abbreviation:  Int J Pharm     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-03-24     Completed Date:  2008-07-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7804127     Medline TA:  Int J Pharm     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  77-81     Citation Subset:  IM    
Bristol-Myers Squibb Co., PO Box 191, New Brunswick, NJ 08903-0191, United States.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Calorimetry, Differential Scanning
Drug Incompatibility
Drug Stability
Drug Storage
Excipients / chemistry*
Povidone / chemistry*
Stearic Acids / chemistry*
Time Factors
X-Ray Diffraction
Reg. No./Substance:
0/Capsules; 0/Excipients; 0/Stearic Acids; 57-11-4/stearic acid; 9003-39-8/Povidone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New options in the treatment of locally advanced head and neck cancer: role for induction chemothera...
Next Document:  Regional variance of visually lossless threshold in compressed chest CT images: lung versus mediasti...